| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $81,871,150 | 25 | 100 |
| Poetting Sierk | Chief Operating Officer | 0 | $0 | 1 | $5.53M | $-5.53M |
| Sahin Ugur | Chief Executive Officer | 0 | $0 | 24 | $76.34M | $-76.34M |
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast …
Over the last 12 months, insiders at BioNTech SE have bought $0 and sold $81.87M worth of BioNTech SE stock.
On average, over the past 5 years, insiders at BioNTech SE have bought $0 and sold $81.87M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-10-09 | Sale | Sahin Ugur | Chief Executive Officer | 36,209 0.0142% | $95.37 | $3.45M | -8.56% | |
| 2026-10-08 | Sale | Sahin Ugur | Chief Executive Officer | 27,000 0.0108% | $92.31 | $2.49M | -3.50% | |
| 2026-10-07 | Sale | Sahin Ugur | Chief Executive Officer | 24,000 0.0096% | $95.86 | $2.3M | -6.55% | |
| 2026-10-06 | Sale | Sahin Ugur | Chief Executive Officer | 21,000 0.0085% | $96.81 | $2.03M | -6.96% | |
| 2026-10-05 | Sale | Sahin Ugur | Chief Executive Officer | 72,000 0.0283% | $97.23 | $7M | -8.72% | |
| 2026-10-02 | Sale | Sahin Ugur | Chief Executive Officer | 17,000 0.0068% | $96.72 | $1.64M | -7.98% | |
| 2026-10-01 | Sale | Sahin Ugur | Chief Executive Officer | 17,000 0.0068% | $97.46 | $1.66M | -7.89% | |
| 2026-09-30 | Sale | Sahin Ugur | Chief Executive Officer | 32,000 0.0127% | $98.12 | $3.14M | -9.01% | |
| 2026-09-29 | Sale | Sahin Ugur | Chief Executive Officer | 34,000 0.0135% | $98.26 | $3.34M | -9.03% | |
| 2026-09-28 | Sale | Sahin Ugur | Chief Executive Officer | 34,000 0.0133% | $98.47 | $3.35M | -9.23% | |
| 2026-09-25 | Sale | Sahin Ugur | Chief Executive Officer | 27,000 0.0107% | $98.69 | $2.66M | -8.45% | |
| 2026-09-24 | Sale | Sahin Ugur | Chief Executive Officer | 39,000 0.0155% | $98.99 | $3.86M | -8.64% | |
| 2026-09-23 | Sale | Sahin Ugur | Chief Executive Officer | 30,000 0.0121% | $99.40 | $2.98M | -7.40% | |
| 2026-09-22 | Sale | Sahin Ugur | Chief Executive Officer | 46,000 0.0192% | $100.72 | $4.63M | -9.56% | |
| 2026-09-21 | Sale | Sahin Ugur | Chief Executive Officer | 33,000 0.0134% | $97.81 | $3.23M | -6.85% | |
| 2026-09-18 | Sale | Sahin Ugur | Chief Executive Officer | 30,000 0.012% | $96.22 | $2.89M | -4.56% | |
| 2026-09-17 | Sale | Sahin Ugur | Chief Executive Officer | 34,000 0.0135% | $98.60 | $3.35M | -6.69% | |
| 2026-09-16 | Sale | Sahin Ugur | Chief Executive Officer | 15,000 0.006% | $96.09 | $1.44M | -2.27% | |
| 2026-09-15 | Sale | Sahin Ugur | Chief Executive Officer | 34,000 0.0135% | $96.49 | $3.28M | -1.49% | |
| 2026-09-14 | Sale | Sahin Ugur | Chief Executive Officer | 41,000 0.0163% | $99.45 | $4.08M | -3.41% |
| Increased Positions | 157 | +45.24% | 9M | +17.65% |
| Decreased Positions | 142 | -40.92% | 11M | -21.03% |
| New Positions | 61 | New | 3M | New |
| Sold Out Positions | 57 | Sold Out | 1M | Sold Out |
| Total Postitions | 362 | +4.32% | 48M | -3.38% |